RT Journal Article SR Electronic T1 Locally advanced non–small cell lung cancer: What is the optimal concurrent chemoradiation regimen? JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP S32 OP S37 DO 10.3949/ccjm.79.s2.07 VO 79 IS 5 e-suppl 1 A1 Gregory M.M. Videtic YR 2012 UL http://www.ccjm.org/content/79/5_e-suppl_1/S32.abstract AB The optimal chemoradiation regimen for patients with locally advanced non–small cell lung cancer (NSCLC) has yet to be defined. Disease and patient heterogeneity prevent a “one size fits all” approach to treatment. Concurrent chemoradiation up front is the definitive strategy for patients with unresectable stage III NSCLC; the addition of consolidation chemotherapy following definitive treatment has produced conflicting results with respect to overall survival. Biologic therapies have yet to show value as add-on treatment to chemoradiation.